Biovest International, Inc. Release: BiovaxID(TM) Yields 89% Survival In Patients With Aggressive Non-Hodgkins Mantle Cell Lymphoma At Median Follow-up Of 3.8 Years

Biovest International, Inc. (OTCBB: BVTI), a subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI), reports follow-up data to a Phase 2 trial conducted by the National Cancer Institute (NCI) that shows Biovest's BiovaxID yielded an 89% survival rate in mantle cell lymphoma patients. The median follow-up was 3.8 years. Historically, patients with this type of lymphoma only have had a 50% chance of surviving 3 years and 20% chance of surviving 5 years. BiovaxID, an investigational personalized anti-cancer vaccine, stimulates the immune system to seek out and destroy tumor cells. The data were published in a recent edition of Nature Medicine (Nat Med.2005; 11(9):986-91).